Choosing antipsychotic maintenance therapy - A naturalistic study

Pharmacopsychiatry

Volumn 33, Issue 2, 2000, Pages 66-71

  Tavcar, R ^a   Dernovsek, M Z ^a   Zvan, V ^a  

^a UNIVERSITY PSYCHIATRIC HOSPITAL   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; BEHAVIOR; FEMALE; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA; SURVIVAL;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MODELS, PSYCHOLOGICAL; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PSYCHOTIC DISORDERS; RECURRENCE; RISK ASSESSMENT; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS;

EID: 0034098753     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-7969     Document Type: Article

References (49)

1. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 (Suppl.): 1-63
2. Balon R: The underutilization of depot neuroleptic therapy. J Clin Psychiatry 1994; 55: 39
3. Barnas C, Stuppäck C, Miller CH, Haring C, Sperner-Unterweger B, Fleischhacker WW.: Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. Int Clin Psychopharmacol 1992; 7: 23-27
4. Barnes TR, Curson DA: Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994; 10: 464-479
5. Borison RL: Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995; 15 (Suppl. 1): 24S-29S
6. Bourin M, Venisse JL, Lecuyer F: Resultats d'une enquête sur l'utilisation en psychiatrie des neuroléptiques a action prolongée. Encephale 1990; 16: 363-369
7. Burnett PL, Galletly CA, Moyle RJ, Clark CR: Low-dose depot medication in schizophrenia. Schizophr Bull 1993; 19: 155-164
8. Chiles JA, Miller AL, Crismon ML, Rush AJ, Krasnoff AS, Shon SS: The Texas medication algorithm project: development and implementation of the schizophrenia algorithm. Psychiatr Serv 1999; 50: 69-74
9. Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, Casey DE, Hassan M: Dose response of prophylactic antipsychotics. J Clin Psychiatry 1993; 54 (Suppl.): 24-30
10. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L: Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47: 741-773
11. Dunn CJ, Fitton A: Sertindole: new drug profile. CNS Drugs 1996; 5: 224-230
12. Fleischhacker WW, Hummer M: Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 1997; 53: 915-929
13. Flynn SW, MacEwan GW, Altman S, Kopala LC, Fredrikson DH, Smith GN, Honer WG: An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 1998; 31: 25-29
14. Glazer WM, Kane JM: Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53: 426-433
15. Hirsch SR, Jolley AG, Barnes TR, Liddle PF, Curson DA, Patel A, York A, Bercu S, Patel M: Dysphoric and depressive symptoms in chronic schizophrenia. Schizophr Res 1989; 2: 259-264
16. Hirschberg E: Long persisting drug-induced parkinsonism - a case report. Pharmacopsychiatry 1987; 20: 278
17. Kane JM, Honigfeld G, Singer J, Meltzer HY, and the Clozaril Collaborative Study Group: Clozapine for the treatment resistant schizophrenia: a double blind comparison study with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796
18. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindström E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR: Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998; 8: 55-66
19. Kissling W: Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand 1994; 89 (Suppl. 382): 16-24
20. Lane H-Y, Liu C-C, Chang W-H: Risperidone for exclusively negative symptoms. Am J Psychiatry 1999; 156: 335
21. Marder SR: The role of dosage and plasma levels in neuroleptic relapse prevention. Acta Psychiatr Scand 1994; 89 (Suppl. 382): 25-27
22. Martyns-Yellowe IS: The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment. West Afr J Med 1994; 13: 200-203
23. Meltzer HY, Hippius H: The assessment and management of treatment-resistant schizophrenia in perspective. Eur Psychiatry 1995; 10 (Suppl. 1): 3s-5s
24. Miyaoka H, Kamijima K: Japanese psychiatrists' impressions on the efficacy and safety of seven antipsychotic drugs. Pharmacopsychiatry 1997; 30: 276
25. Nuechterlein KH, Dawson ME, Ventura J, Gitlin M, Subotnik KL, Snyder KS, Mintz J, Bartzokis G: The vulnerability/stress model of schizophrenic relapse: a longitudinal study. Acta Psychiatr Scand 1994; 89 (Suppl. 382): 58-64
26. Nyberg S, Farde L, Halldin C: Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Arch Gen Psychiatry 1997; 54: 953-958
27. Pabis DJ, Dorson PG, Crismon ML: Evaluation of inpatient depot antipsychotic prescribing. Ann Pharmacother 1996; 30: 1381-1386
28. Pereira S, Pinto R: A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997: 95: 464-468
29. Remington GJ, Adams ME: Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995; 40 (Suppl. 1): S5-S11
30. Schwartz JT, Brotman AW: A clinical guide to antipsychotic drugs. Drugs 1992; 44: 981-992
31. Salvador-Carulla L, Rodriguez-Blázquez C: Psychosocial modifiers of drug prescription: the hidden face of pharmacology? Pharmacoepidemiol Drug Saf 1998; 7: 23-30
32. Silverstone T: Clinically relevant differences between antipsychotic compounds. Acta Psychiatr Scand 1990; 82 (Suppl. 358): 88-91
33. Solgaard T, Kistrup K, Aaes-Jorgensen T, Gerlach J: Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients. Minimum effective dose and corresponding serum levels. Pharmacopsychiatry 1994; 27: 119-123
34. Soni SD, Sampath G, Shah A, Krska J: Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation. Acta Psychiatr Scand 1992; 85: 354-359
35. Soni SD, Gaskell K, Reed P: Factors affecting rehospitalisation rates of chronic schizophrenic patients living in the community. Schizophr Res 1994; 12: 169-177
36. Tavcar R, Dernovsek MZ: Recidivism in Slovenia. Psychiatr Serv 1997; 48: 955-956
37. Thomas CS, Lewis S: Which atypical antipsychotic? Br J Psychiatry 1998; 172: 106-109
38. Tollefson GD: Olanzapine: novel antipsychotic with a broad spectrum profile. Neuropsychopharmacology 1994; 10: 805
39. Trenckmann U: Wirkungen und Nebenwirkungen der Depot-Neuroleptika im Erleben des Patienten. Psychiatr Prax 1990; 17: 184-187
40. Tuninger E, Levander S: Large variations of plasma levels during maintenance treatment with depot neuroleptics. Br J Psychiatry 1996; 169: 618-621
41. Tuninger E, Levander S: Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients. Acta Psychiatr Scand 1997; 96: 347-353
42. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Token M: Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54: 49-55
43. Voirol P, Robert PA, Meister P, Oros L, Baumann P: Psychotropic drug prescription in a psychiatric university hospital. Pharmacopsychiatry 1999; 32: 29-37
44. Zvan V: Nacela vzdrzevalne nevrolepticne terapije psihoz. Zdravstveno Varstvo 1989; 28: 335-341
45. Wei FC, Jann MW, Lin HN, Piao Chen C, Chang WH: A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. J Clin Psychiatry 1996; 57: 298-302
46. Weiden P, Schooler NR, Severe JB, Lee JH, Schulz SC: Stabilization and depot neuroleptic dosages. Psychopharmacol Bull 1993; 29: 269-275
47. Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A: Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995; 46: 1049-1054
48. Weiden P, Aquila R, Standard J: Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57 (Suppl. 11): 53-60
49. Wing JK, Cooper JE, Sartorius N: Measurement and classification of psychiatric symptoms. Cambridge. University Press 1974